Satellos Bioscience Inc.
MSLEHealthcare|Biotechnology|CA
$7.19
+0.84 (+13.23%)
DCF Value
$4.97
Tangible Book / Share
$2.87
Cash / Share
$2.96
Analyst Consensus
Buy1 analysts
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Consensus Target
$20.00
Implied Upside
+178.2%
Low Target
$18.00
High Target
$24.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
$24.00
1 target · +234% vs price
Last Year
$20.75
4 targets · +189% vs price
All Time
$20.75
4 targets · +189% vs price
Rating Trend
Feb 26
1 buy · 0 hold · 0 sell
Mar 26
2 buy · 0 hold · 0 sell
Apr 26
4 buy · 0 hold · 0 sell
May 26
4 buy · 0 hold · 0 sell
Jun 26
4 buy · 0 hold · 0 sell
Jul 26
5 buy · 0 hold · 0 sell
Aug 26
6 buy · 0 hold · 0 sell
Sep 26
8 buy · 0 hold · 0 sell
Oct 26
8 buy · 0 hold · 0 sell
Nov 26
9 buy · 0 hold · 0 sell
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 8, 2026 | Craig-Hallum | $24.00(+215%) | $7.63 | TheFly | |
| Jul 9, 2026 | Wells Fargo | $18.00(+100%) | $8.98 | StreetInsider | |
| Jul 9, 2026 | H.C. Wainwright | $18.00(+100%) | $8.98 | TheFly | |
| Apr 28, 2026 | Guggenheim | $23.00(+221%) | $7.16 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2026 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.60| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.56 | $-0.38 | — | — |
| May 14, 2026 | $-0.53 | $-0.51 | — | — |
| Mar 27, 2026 | $-0.47 | $-0.36 | — | — |
| Nov 14, 2025 | $-0.36 | $-0.33 | — | — |
| Aug 13, 2025 | $-0.36 | $-0.27 | — | — |
| May 13, 2025 | $-0.47 | $-0.38 | — | — |
| Mar 26, 2025 | $-0.50 | $-0.34 | — | — |
| Nov 13, 2024 | $-0.71 | $-0.44 | — | — |
News
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
Shares of Satellos Bioscience Inc. (NASDAQ: MSLE - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the
Sep 28, 2026defenseworld.net